DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rk84gc/china_large) has announced the addition of the "China Large Volume Parenteral (LVP) Industry Report, 2013-2015" report to their offering.
Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese preparations have grown year by year. In 2006-2012, China's injection output presented the CAGR of 19.2%. However, due to the low barriers to entry, China has seen some signs of the surplus injection capacity, which exceeds the demand by roughly 40%.
Overcapacity and fierce competition are caused by the irrational injection product structure and homogeneity. For example, the output and sales volume of fluid balance injection products with low added value account for 89% of the injection market, but the sales revenue only shares 47%. At the same time, the market demand for amino acids, fat emulsion dual-chamber bags, fat emulsion, total parenteral nutrition, hydroxyethyl starch and unique traditional Chinese medicine injection is quite strong.
Compared to Europe and other developed countries, the concentration degree of Chinese LVP market is still lower. At present, 200 ones of 400 qualified Chinese LVP enterprises run business soundly. By output, the top 10 Chinese companies contribute about 65%; in terms of sales revenue, they devote about 40 %.
Like other chemical preparation segments, Chinese high-end LVP market is still dominated by foreign pharmaceutical companies.
Key Topics Covered
1 Overview of LVP
1.1 Definition and Classification
1.2 Industry Chain
2 Overview of China LVP Industry Development
2.1 Status Quo
2.2 Competition Pattern
2.3 Product Structure
2.4 Regional Distribution
2. 5 Development Forecast
3 Chinese LVP Market Segments
3.1 Injection for Fluid Balance
3.2 Therapeutic Injection
3.3 Nutritious Injection
3.4 Injection for Blood Volume Expansion
3.5 Peritoneal Dialysis Solution
4 Main Companies
5 China LVP Industry Summary and Development Prediction
5.1 Market Size to Ascend but Capacity Growth to Slow Down
5.2 Industry Concentration to Improve and Large Players with obvious Competitive Edges
5.3 Product Structure to Upgrade and New LVP products Development to be Trend
Companies Mentioned
- China Otsuka Pharmaceutical
- China Resources Double-Crane
- Fengyuan Pharmaceutical
- Huaren Pharmaceutical
- Jilin Dubang Pharmaceutical
- Kelun Pharma
- Lijun International Pharmaceutical (Holding)
- Qingzhou Yaowang Medicine
- Shandong Lukang Cisen Pharmaceutical
- Shijiazhuang No.4 Pharmaceutical
- Southwest Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/rk84gc/china_large
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
